Pancreatic enzymes (medication)

Pancreatic enzymes, also known as pancreases, pancrelipases or pancreatins are commercial mixtures of amylase, lipase, protease and lactase[3] obtained from pigs. The components are digestive enzymes similar to those normally produced by the human pancreas.[4] They help in the digestion of fats, starches, and proteins. They are used to treat malabsorption syndrome due to certain pancreatic insufficiencies. These pancreatic problems may be due to cystic fibrosis, surgical removal of the pancreas, long-term pancreatitis, pancreatic cancer, or MODY 5, among others. The preparation is taken by mouth.[5] The treatment is also known as pancreatic enzyme replacement therapy or PERT.[6]

Common side effects include vomiting, abdominal pain, constipation, and diarrhea.[5] Other side effects include perianal irritation and high blood uric acid. Use is believed to be safe during pregnancy.[7]

Pancreatic enzymes have been used as medications since at least the 1800s.[8] They are on the World Health Organization's List of Essential Medicines.[9] In 2023, it was the 258th most commonly prescribed medication in the United States, with more than 1million prescriptions.[10][11]

Medical uses

Pancrelipases are generally a first line approach in treatment of exocrine pancreatic insufficiency and other digestive disorders, accompanying cystic fibrosis, complicating surgical pancreatectomy, or resulting from chronic pancreatitis. The formulations are generally hard capsules filled with gastro-resistant granules. Pancrelipases and pancreatins are similar, except pancrelipases has an increased lipase component.

Pancreatin is a mixture of several digestive enzymes produced by the exocrine cells of the pancreas. It is composed of amylase, lipase and protease. This mixture is used to treat conditions in which pancreatic secretions are deficient, such as surgical pancreatectomy, pancreatitis and cystic fibrosis.[12][13] It has been claimed to help with food allergies, celiac disease, autoimmune disease, cancer and weight loss. Pancreatin is sometimes called "pancreatic acid", although it is neither a single chemical substance nor an acid.

A similar mixture of enzymes is sold as pancrelipase, which contains more active lipase enzyme than does pancreatin. The trypsin found in pancreatin works to hydrolyze proteins into oligopeptides; amylase hydrolyzes starches into oligosaccharides and the disaccharide maltose; and lipase hydrolyzes triglycerides into fatty acids and glycerols. Pancreatin is an effective enzyme supplement for replacing missing pancreatic enzymes, and aids in the digestion of foods in cases of pancreatic insufficiency.[14]

Pancreatin reduces the absorption of iron from food in the duodenum during digestion.[15]

Some contact lens-cleaning solutions contain porcine pancreatin extractives to assist in the intended protein-removal process.[16]

Side effects

High doses over a long period of time are associated with fibrosing colonopathy.[17] Due to this association a maximum dose of 10,000 IU of lipase per kilogram per day is recommended.[18]

Though never reported there is a theoretical risk of a viral infection as they are from pigs.[19]

Society and culture

Brand names

Brand names include Creon,[20] Pancreaze, Pertzye, Sollpura[21] (Liprotamase[22][23]), Ultresa,[24] and Zenpep.[25]

In some countries, Creon is marketed by Viatris after Upjohn merged with Mylan to create Viatris.[26][27]

United States

Longstanding pancreatic enzyme replacement products (PERPs)—some in use for a century or more—fell under a 2006 FDA requirement that pharmaceutical companies with porcine-derived PERP products submit a New Drug Application (NDA) for each; Creon (AbbVie Inc.), the first of the commercial PERP products approved after the FDA directive, reached market in 2009.[20]

The specific requirement and reasoning for the FDA directive was that manufacturers submit a Risk Evaluation and Mitigation Strategy (REMS) and Medication Guide to ensure patients are adequately informed regarding potential risks associated with administration of high doses of porcine-derived PERP products, especially with regard to "the theoretical risk of transmission of viral disease from pigs to patients", the risk of which (alongside other off-target effects) is reduced by patient adherence to label dosing instructions.[20]

United States

Longstanding pancreatic enzyme replacement products (PERPs)—some in use for a century or more—fell under a 2006 FDA requirement that pharmaceutical companies with porcine-derived PERP products submit a New Drug Application (NDA) for each; Creon (AbbVie Inc.), the first of the commercial PERP products approved after the FDA directive, reached market in 2009.[20]

The specific requirement and reasoning for the FDA directive was that manufacturers submit a Risk Evaluation and Mitigation Strategy (REMS) and Medication Guide to ensure patients are adequately informed regarding potential risks associated with administration of high doses of porcine-derived PERP products, especially with regard to "the theoretical risk of transmission of viral disease from pigs to patients", the risk of which (alongside other off-target effects) is reduced by patient adherence to label dosing instructions.[20]

Shortages and alternatives

Due to its non-constant supply, being sourced from pigs, there have been several pancreatin shortages in different markets.[28][29][30]

This has led for alternative sources of enzymes to be studied and commercialised, mainly being of bacterial or fungal origin.[31][32]

References

  1. Pancrelipase Uses, Side Effects & Warnings^
  2. Micrazym and associated names European Medicines Agency, 21 March 2024, retrieved 13 June 2024^
  3. Pancreatin The American Society of Health-System Pharmacists, retrieved 8 January 2017^
  4. Understanding Pharmacology for Pharmacy Technicians ASHP, 2013^
  5. Pancrelipase The American Society of Health-System Pharmacists, retrieved 8 January 2017^
  6. Pancreatic enzyme replacement therapy (PERT) Pancreatic Cancer UK, retrieved 28 February 2025^
  7. British national formulary: BNF 69 British Medical Association, 2015^
  8. Genomics, Proteomics and Metabolomics in Nutraceuticals and Functional Foods John Wiley & Sons, 2015^
  9. World Health Organization model list of essential medicines: 21st list 2019 World Health Organization, 2019^
  10. The Top 300 of 2023 ClinCalc, retrieved 17 August 2025^
  11. Pancrelipase Amylase; Pancrelipase Lipase; Pancrelipase Protease Drug Usage Statistics, United States, 2014 - 2023 ClinCalc, retrieved 17 August 2025^
  12. Study to compare the enzyme activity, acid resistance and dissolution characteristics of currently available pancreatic enzyme preparations Pharmaceutisch Weekblad. Scientific Edition, February 1988^
  13. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency European Journal of Gastroenterology & Hepatology, September 2009^
  14. PDF version Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study Alimentary Pharmacology & Therapeutics, September 2012^
  15. Iron Deficiency and Iron Overload Archives of Disease in Childhood, August 1965^
  16. Adsorption and removal of protein bound to hydrogel contact lenses Optometry and Vision Science, November 1990^
  17. Cystic fibrosis colonopathy Current Gastroenterology Reports, June 1999^
  18. Proper usage of pancreatic enzymes Current Opinion in Pulmonary Medicine, November 2002^
  19. CREON® (pancrelipase) Delayed-Release Capsule www.creon.com, retrieved 10 October 2019^
  20. U.S. Food and Drug Administration. FDA Approves Pancreatic Enzyme Replacement Product for Marketing in United States: Creon designed to help those with cystic fibrosis, others with exocrine pancreatic insufficiency News & Events, FDA News Release, 7 May 2009, retrieved 20 July 2014^
  21. Anthera's Sollpura canned after phase 3 flop, shares plunge Fierce Biotech, 12 March 2018, retrieved 23 October 2021^
  22. FDA Committee Declines to Recommend Liprotamase for EPI The Boomer Esiason Foundation, 19 March 2019, retrieved 22 May 2021^
  23. Did not make it past Phase 3 trials^
  24. Ultresa - Search results. Page 1 of about 39 results Drugs.com, retrieved 22 May 2021^
  25. Zenpep: Uses, Dosage & Side Effects Information Drugs.com, retrieved 22 May 2021^
  26. Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan Pfizer, 16 November 2020, retrieved 17 June 2024^
  27. Brands Viatris, 16 November 2020, retrieved 17 June 2024^
  28. Pancreatic cancer action. Temporary shortage of Creon (Pancreatin) 25k Pancreatic cancer news, 21 April 2020, retrieved 15 July 2020^
  29. Mylan. Pancreatin - Cambridgeshire and Peterborough CCG 1 February 2019, retrieved 15 July 2020^
  30. Greater Glasgow and Clyde Medicines. Medicines Update Primary Care July 2016, retrieved 15 July 2020^
  31. Lipase supplementation therapy: standards, alternatives, and perspectives Pancreas, January 2003^
  32. The role of enzyme supplementation in digestive disorders Alternative Medicine Review, December 2008^